Management of Barrett's Esophagus with Proton Pump Inhibitors

Recommended Dosing Strategy

The British Society of Gastroenterology recommends omeprazole 20mg twice daily (total 40mg/day) for managing Barrett's esophagus, providing superior acid suppression compared to once-daily regimens 1, 2
Omeprazole 20mg twice daily is the recommended dose for adequate symptom control and acid suppression in patients with Barrett's esophagus, according to the British Society of Gastroenterology guidelines 1, 2

The British Society of Gastroenterology states that PPIs are recommended primarily for symptom control in Barrett's esophagus, not chemoprevention, with a recommendation grade of C 1, 2
PPIs have the best clinical profile for symptomatic management of Barrett's esophagus, with a recommendation grade of A 1, 2
The American Gastroenterological Association recommends against attempts to eliminate esophageal acid exposure specifically for prevention of esophageal adenocarcinoma 3, 4

Patients with persistent symptoms on 20mg twice daily may require dose escalation, though this should be guided by symptom response rather than pH monitoring 3, 4
Long-term PPI use carries risks including osteoporosis, GI infections, and pneumonia that must be balanced against benefits 1, 2
The 2022 AGA guidance on PPI de-prescribing specifically identifies Barrett's esophagus as a definitive indication for long-term PPI use, meaning these patients should generally not be considered for discontinuation 5
Dose adjustments should be based on symptom control, not routine pH monitoring 3, 4
Patients should continue surveillance endoscopy according to established guidelines regardless of PPI dose 1, 2